-
Product Insights
NewProstaglandin G/H Synthase 2 – Drugs In Development, 2024
The Prostaglandin G/H Synthase 2 pipeline drugs market research report outlays comprehensive information on the Prostaglandin G/H Synthase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Immunology, Musculoskeletal Disorders, and Oncology which include indications of Pain, Post-Operative Pain, Inflammation, Rheumatoid Arthritis, Osteoarthritis, Muscle Spasm, Solid Tumor, and Non-Small Cell Lung Cancer. It also...
-
Product Insights
NewComplement Factor H – Drugs In Development, 2024
The Complement Factor H pipeline drugs market research report outlays comprehensive information on the Complement Factor H targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Genito Urinary System, Ophthalmology, and Immunology which include indications of Oncology, Breast Cancer, Kidney Disease (Nephropathy), Geographic Atrophy, Choroidal Neovascularization, Autoimmune Disorders, and Chronic Inflammation. It also reviews key players involved...
-
Product Insights
NewProstaglandin G/H Synthase 1 – Drugs In Development, 2024
The Prostaglandin G/H Synthase 1 pipeline drugs market research report outlays comprehensive information on the Prostaglandin G/H Synthase 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Immunology, Musculoskeletal Disorders, and Cardiovascular which include indications of Pain, Post-Operative Pain, Inflammation, Rheumatoid Arthritis, Osteoarthritis, Muscle Spasm, Patent Ductus Arteriosus, and Myocardial Infarction. It also reviews...
-
Sector Analysis
NewHome Retail Market Size, Trends and Analysis by Regional and Category Performance, Key Retailers and Forecast to 2028
This report provides an overview of the global home retail sector which includes analysis, drivers, inhibitors, market forecasts, brands and trends in the global home market between 2023 and 2028 During the COVID-19 lockdowns, the global home market experienced a significant increase in spending, growing by 15.7% in 2021. However, spending declined in 2022 and 2023 as the market began to normalize, influenced by high inflation and diminished consumer confidence, which adversely affected expenditure on large-ticket items and home renovations....
-
Sector Analysis
NewUnited Kingdom (UK) Ramadan/Eid – Analysing Trends and Consumer Shopping Attitudes
United Kingdom (UK) Ramadan/Eid Market Report Overview Female consumer participation penetration was higher than male consumers in the Ramadan/Eid market in the UK. London has the highest participation penetration followed by Yorkshire and the Humber. Female consumers dominated the shopper penetration and shopper profile. The UK Ramadan/Eid market research report offers a comprehensive insight into the dynamics and spending habits of UK consumers for Ramadan/Eid. The report also analyzes the major players and consumer attitudes to identify the target audience...
-
Product Insights
NewDementia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Dementia - Global Clinical Trials Review, 2024" provides an overview of Dementia Clinical trials scenario. This report provides top line data relating to the clinical trials on Dementia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Consumer Insights
NewMexico Apparel Market Size, Consumer Insights, Competitive Landscape and Forecast to 2028
This report provides a country snapshot of Mexico's apparel market. The report provides market data on the apparel market size in Mexico, total and online, top brands in the apparel market by market share, the competitive landscape for leading retailers, and consumer insight including how Mexican consumers feel about inflation and how they are adapting their shopping habits. The report also includes key themes in the Mexico apparel market, including commentary on the luxury, resale and sportswear markets. In 2023,...
-
Sector Analysis
NewIndia General Insurance Market Size and Trends by Line of Business, Distribution, Competitive Landscape and Forecast to 2028
India General Insurance Market Report Overview The gross written premium of the Indian general insurance market was INR3 trillion ($36.5 billion) in 2023. The Indian general insurance sector growth peaked in 2022 and slowed down the following year majorly due to a decrease in liability, crop, credit guarantee, and marine, aviation, and transit (MAT) insurance premiums. The growth is anticipated to slow down over 2024–28 at a CAGR of more than 9%, due to elevated interest rates and medical inflation....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anamorelin Hydrochloride in Fatigue
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anamorelin Hydrochloride in Fatigue report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anamorelin Hydrochloride in Fatigue Drug Details: Anamorelin hydrochloride (Adlumiz) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eptinezumab in Cluster Headache Syndrome (Cluster Headache)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eptinezumab in Cluster Headache Syndrome (Cluster Headache) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eptinezumab in Cluster Headache Syndrome (Cluster Headache) Drug...